$BWAY

A roundup of Monday analyst actions includes Morgan Stanley reiterating Nvidia (overweight) and Broadcom (overweight), with a focus on data center memory-cycle signals. BMO downgraded Charles Schwab to market perform. Cantor reiterated Tesla overweight ahead of earnings. Other calls include price targets for Versigent, Crane, Lumentum, and Apple, plus initiations for BP and TotalEnergies.

Roth Yiftach (Chief Scientist) sold 2,000 shares of Brainsway Ltd. (BWAY) on 2026-06-02.

Roth Yiftach (Chief Scientist) sold 1,000 shares of Brainsway Ltd. (BWAY) on 2026-06-02.

Roth Yiftach (Chief Scientist) sold 2,000 shares of Brainsway Ltd. (BWAY) on 2026-06-01.

Roth Yiftach (Chief Scientist) sold 2,000 shares of Brainsway Ltd. (BWAY) on 2026-06-01.

PRISM MarketView highlighted seven public companies developing mental health therapies, devices, and digital platforms during National Mental Health Awareness Month. Featured firms include Helus Pharma (HELP), GH Research (GHRS), AtaiBeckley (ATAI), Definium Therapeutics (DFTX), BrainsWay (BWAY), Neuronetics (STIM), and Talkspace (TALK), spanning psychedelic-derived treatments, TMS, and virtual care.

Mitrany Rayten Michal Ety sold 10,000 shares of Brainsway Ltd. (BWAY) on 2026-05-25.

BrainsWay Ltd. (NASDAQ:BWAY) reported strong Q1 2026 results, surpassing analyst estimates with adjusted EPS of $0.06 and revenue growth of 35% year-over-year to $15.5 million. Despite beating expectations and shipping a record number of Deep TMS systems, the company's stock fell over 2% in pre-market trading as investors reacted to its reiterated full-year guidance, which remained largely in line with analyst consensus. BrainsWay also highlighted significant progress in expanding Deep TMS awareness, broader reimbursement, and secured the first insurer coverage for its accelerated SWIFT Deep TMS protocol.

BrainsWay, a leader in neurostimulation treatments, has invested $1.0 million, with a potential for an additional $1.5 million, in BrainStim Health Inc., a Canadian mental health provider. This minority-stake investment aims to expand access and awareness of Deep TMS technology in North America. BrainsWay views this as part of a broader strategy to support growth-oriented clinical service platforms while focusing on scientific and clinical advancement.

BrainsWay has highlighted a policy change by Cigna Group’s Evernorth Behavioral Health, effective March 6, 2026, which will remove prior authorization for transcranial magnetic stimulation (TMS) coverage for contracted providers. This decision is expected to broaden access to Deep TMS for patients with major depressive disorder and obsessive-compulsive disorder across 12 states and strengthen BrainsWay's position in the U.S. TMS market. An analyst has a Buy rating on BWAY stock with a target of $29.00.